Lipid Management in Clinical Practice (MK-0524A-115)
|ClinicalTrials.gov Identifier: NCT01071278|
Recruitment Status : Completed
First Posted : February 19, 2010
Results First Posted : March 7, 2012
Last Update Posted : August 11, 2015
|Condition or disease|
|Lipid Metabolism Disorder|
|Study Type :||Observational|
|Actual Enrollment :||2390 participants|
|Official Title:||Lipid Management in Clinical Practice|
|Study Start Date :||October 2009|
|Actual Primary Completion Date :||February 2011|
|Actual Study Completion Date :||February 2011|
Patients treated within a disease management program
Participant prescribed Tredaptive® for dyslipidemia and also participated in a disease management program for treatment of diabetes mellitus, coronary heart disease or both.
Patients treated outside a disease management program
Participant prescribed Tredaptive® for dyslipidemia and did not participate in a disease management program for treatment of diabetes mellitus, coronary heart disease or both.
- Number of Participants With Lipid Panel Control [ Time Frame: From Visit 1 entrance evaluation (Week 0) to Visit 2 (between Weeks 8-22) ]Lipid Panel Control was defined as achieving target for one or more of the following parameters: low-density lipoprotein cholesterol (LDL-C) at goal (<100mg/dL), high-density lipoprotein cholesterol (HDL-C) within normal range (40mg/dL for males and 50mg/dL for females), and/or triglycerides within normal range (≤ 150mg/dL).
- Number of Participants Who Reported Adverse Events [ Time Frame: Up to 22 weeks ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01071278
|Study Director:||Medical Monitor||Merck Sharp & Dohme Corp.|